Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020

BACKGROUND: Monoclonal antibody (mAb) and Fc-fusion protein (FcP) are highly effective therapeutic biologics. We aimed to analyse consumption and expenditure trends in 14 Asia-Pacific countries/regions (APAC) and three benchmark countries (the UK, Canada, and the US). METHODS: We analysed 440 mAb an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Xinning, Li, Xue, Pratt, Nicole L., Hillen, Jodie B., Stanford, Tyman, Ward, Michael, Roughead, Elizabeth E., Lai, Edward Chia-Cheng, Shin, Ju-Young, Cheng, Franco W.T., Peng, Kuan, Lau, Chak Sing, Leung, Wai Keung, Wong, Ian C.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249810/
https://www.ncbi.nlm.nih.gov/pubmed/35789824
http://dx.doi.org/10.1016/j.lanwpc.2022.100506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249810/
https://www.ncbi.nlm.nih.gov/pubmed/35789824
http://dx.doi.org/10.1016/j.lanwpc.2022.100506

Ejemplares similares